Boehringer backs AI-powered anti-infective startup ArrePath
pharmaphorum
MARCH 7, 2022
A new company set up to use machine learning to find new anti-infective drugs – ArrePath – has launched onto the scene with $20 million in seed financing from a group of investors including the Boehringer Ingelheim Venture Fund. The Princeton, New Jersey-based startup will use the funding to develop its artificial intelligence and imaging based drug discovery platform, used to identify compounds with new and under-exploited mechanisms of action.
Let's personalize your content